PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting

Area of Science:

• Pharmacogenomics
• Clinical Genetics

Background:

• The CYP2D6 gene locus is highly polymorphic, significantly impacting drug metabolism, efficacy, and safety.
• Accurate prediction of patient CYP2D6 phenotype requires comprehensive testing, including structural variants like deletions, duplications, and hybrid genes.
• Lack of standardized nomenclature for CYP2D6 structural variants complicates clinical and research reporting.

Approach:

• This tutorial provides a comprehensive overview of CYP2D6 structural variation, including definitions and terminology.
• It reviews methods for detecting and characterizing these complex structural variants.
• Practical examples are offered to illustrate the application of standardized reporting.

Key Points:

• PharmVar establishes standardized nomenclature for the human CYP2D6 gene locus.
• Detecting structural variants (deletions, duplications, hybrids) is essential for accurate phenotype prediction.
• Uniform reporting of CYP2D6 variants is critical for electronic health records and guiding drug therapy.

Conclusions:

• Standardized nomenclature and reporting of CYP2D6 structural variants improve the accuracy of genotype-to-phenotype translation.
• This guidance facilitates consistent clinical and research reporting, enhancing patient care.
• Adoption of these standards supports the effective use of pharmacogenomics in personalized medicine.